Ribavirin dose reduction during telaprevir/ribavirin/peg‐interferon therapy overcomes the effect of the ITPA gene polymorphism

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2893|22|2|166-174

ISSN： 1352-0504

Source： JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol.22, Iss.2, 2015-02, pp. : 166-174

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. 3, 2015-03 ,pp. : 254-262

John Wiley & Sons Inc

Access to resources Recommend Favorite

Eicosapentaenoic Acid Could Permit Maintenance of the Original Ribavirin Dose in Chronic Hepatitis C Virus Patients during the First 12 Weeks of Combination Therapy with Pegylated Interferon-α and Ribavirin

By  

Intervirology, Vol. 50, Iss. 6, 2008-02 ,pp. : 439-446

Karger

Access to resources Recommend Favorite

Prediction of Treatment Outcome in Chronic Hepatitis C Patients Based on Early Viral Dynamics during High-Dose Induction Interferon and Ribavirin Therapy

By  

Intervirology, Vol. 48, Iss. 4, 2005-05 ,pp. : 230-238

Karger

Access to resources Recommend Favorite

Efficacy in Patients with Dose Reduction in Combination Therapy of Peginterferon and Ribavirin for Chronic Hepatitis C

By  

Intervirology, Vol. 51, Iss. 1, 2008-02 ,pp. : 1-6

Karger

Access to resources Recommend Favorite

Sensitivity to interferon in genotype 2

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 30, Iss. 2, 2015-02 ,pp. : 337-344

John Wiley & Sons Inc

Access to resources Recommend Favorite